Abstract:Histone deacetylase inhibitors (HDACi) such as trichostatin A (TSA) and Sodium Butyrate (NaB) can regulate gene expression by acetylating histones and transcription factors. HDACi attenuate expression of certain NF-kB-regulated cytokines, including TNF-α, IL-1β, IL-6, and IFN-γ in some inflammatory disease models. Human tissue fatctor (TF) expression is, in part, governed by a unique, NF-kB-related “TF-kB” promoter binding site. We hypothesized that HDACi would inhibit induction of TF expression by physiologic agonists. We assessed the effect of TSA and NaB upon TF expression in human umbilical vein endothelial cells (HUVEC) and peripheral blood mononuclear cells (PBM) in response to 1 ng/ml TNF-α, 1 ng/ml IL-1β, 1 μg/ml LPS, and 100 μM HOSCN, a potent phagocyte peroxidase-derived oxidant. HUVEC monlayers and PBM were pretreated with TSA (0.01–1 μM) or NaB (1–10 mM) for 4 h prior to agonist addition and 4 h later whole cell lysates were assayed for TF activity by 1-stage clotting assay and western blots probed for TF. Both TSA and NaB inhibit HUVEC TF activity and protein expression up to 90% with respective IC50's of 30–50 nM and 2 mM. TSA decreases PBM TF activity induced by LPS and IL-1β by 50–65% with similar potency. In striking contrast, western blots show no effect of TSA on agonist-induced expression of the NF-kB-regulated adhesion molecules ICAM-1 and E-selectin. RT-PCR analysis shows TNF-α stimulation induces a 22-fold increase of TF mRNA that is attenuated up to 70% by TSA treatment without affecting the 10-fold ICAM-1 mRNA increase. TSA did not influence TF translational efficiency as detected by polyribosomal TF mRNA distribution and TSA TF inhibition was unaffected by the ubiquitin-dependent protein degradation inhibitor MG-132. EMSA analysis of HUVEC nuclear extracts using probes for the SP1, AP-1, Egr-1 and TF-kB transcription factor binding sites in the TF gene promoter shows that SP1, AP-1 and Egr-1 are constitutively activated in HUVEC and are unaffected by LPS or TNF-α irrespective of whether TSA is present. However, both TNF-α and LPS induce abundant p65/p50 and p65/c-Rel heterodimer binding to both the NF-kB and TF-kB probes. 0.3 μM TSA nearly completely abolishes TF-kB activation without affecting NF-kB activation. TSA has no effect on TNF-α-induced cytoplasmic IkB-α degradation or nuclear translocation of c-Rel, p65, or p50. Chromatin immunoprecipitation assay shows that TSA strongly inhibits p65 binding to the authentic endogenous HUVEC TF-kB site in the TF promoter induced by TNF-α without affecting p65 binding to the ICAM-1 NF-kB site. A HUVEC promoter-luciferase reporter system confirms the complete specificity of TSA's inhibitory effect on LPS- or TNF-α- induced TF expression for TF-kB rather than NF-kB. We conclude that HDACi transcriptionally inhibit agonist-induced TF expression in human endothelial cells and monocytes by specific blockade of TF-kB activation. We propose that histone deacetylases play a previously unsuspected role in regulating TF expression and HDACi might be a novel therapy for thrombotic diseases.

Effects of trichostatin A on the expressions of inflammatory cytokines and toll-like receptor 4 and the acetylation of nuclear factor-κB induced by lipopolysaccharide in macrophage

Effects of Salidroside on the Secretion of Inflammatory Mediators Induced by Lipopolysaccharide in Murine Macrophage Cell Line J774.1

[The Effects of a Histone Deacetylase (HDAC) Inhibitor on Endotoxin-Induced Endothelial Cell Injury].

The effect of histone deacetylase inhibitor ACY1215 on the inflammatory response in mice with acute liver failure

Trichostatin A Increases the TIMP-1/MMP Ratio to Protect Against Osteoarthritis in an Animal Model of the Disease.

Effects of TSA on Cerebral Ischemia/reperfusion Injury Via JAK/STAT Signal Pathway in Rats

“Tf-Kb”-dependent Suppression of Agonist-Mediated Tissue Factor Induction by Histone Deacetylase Inhibitors in Human Endothelial Cells and Monocytes.

Trichostatin A inhibits dendritic cell maturation through down-regulating NF-κ B (p65) pathway

Trichostatin A Inhibits Expression of Cathepsins in Experimental Osteoarthritis

Anti-inflammatory Effects of Ganoderma Lucidum Sterols Via Attenuation of the P38 MAPK and NF-κB Pathways in LPS-induced RAW 264.7 Macrophages

MAPK and NF-κB Up-Regulated the Expression of Toll-Like Receptor 4 Induced by LPS in Pulmonary Micro-Vascular Endothelial Cell in Mouse

Pan HDACi Valproic Acid and Trichostatin A Show Apparently Contrasting Inflammatory Responses in Cultured J774A.1 Macrophages

Histone Deacetylase Inhibitors Suppress TF-κB-dependent Agonist-driven Tissue Factor Expression in Endothelial Cells and Monocytes

TSA Increases C/EBP-α Expression by Increasing Its Lysine Acetylation in Hepatic Stellate Cells

Chromium Alters Lipopolysaccharide-Induced Inflammatory Responses Both in Vivo and in Vitro.

The Anti-Inflammatory Effects of Interferon Tau by Suppressing NF-κB/MMP9 in Macrophages Stimulated with Staphylococcus Aureus.

Suppressive effect of tanshinone ⅡA on HMGB1 release from lipopolysaccharide-induced macrophages

A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture

Trichostatin A Inhibits the Activation of Hepatic Stellate Cells by Increasing C/EBP-α Acetylation in Vivo and in Vitro.

Alleviation of Osteoarthritis by Trichostatin A, a Histone Deacetylase Inhibitor, in Experimental Osteoarthritis

Trichostatin a Protects Dendritic Cells Against Oxygen-Glucose Deprivation via the SRSF3/PKM2/Glycolytic Pathway